Valirx (VAL)

 

VAL Share PerformanceMore

52 week high20.5950 10/02/16
52 week low4.6880 09/01/17
52 week change -12.0000 (-70.59%)
4 week volume14,800,792 27/12/16

Media for (VAL)

Presenter: Suzanne Dilly
01/12/2016
Presenter: Suzanne Dilly
02/11/2016

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ValiRx notes positive VAL201 clinical trial

ValiRx announces positive results in its VAL201 personalised Phase l/II prostate cancer study with accumulation of safety a...

CLINICAL TRIAL UPDATE - Positive VAL201 Results

RNS Number: 8311T ValiRx PLC 11 January 2017 y Va li R x P lc ("ValiRx" or "the Company") CLINICAL TRIAL UPDATE 'Positive VAL201 Results' London, UK ., 11 January 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces positive results in its VAL201 personalised Phase l/II prostate cancer study with accumulation of safety and to...

ValiRx notes Yorkville CLN conversion

ValiRx said YA Global Master SPV Ltd (Yorkville) has elected to convert a further portion of tranche 1 of the Convertible...

Yorkville CLN Conversion

RNS Number: 0006T ValiRx PLC 30 December 2016 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Yorkville CLN Conversion London, UK ., 29 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards comm...

ValiRx says European patent granted for VAL201

ValiRx said a patent (Anti-Androgen Peptides and Uses Thereof in Cancer Therapy) covering its lead therapeutic compoun...

European Patent Granted for Lead Compound VAL201

RNS Number: 2297R ValiRx PLC 08 December 2016 Va li R x P lc ("ValiRx" or "the Company") EUROPEAN PATENT GRANTED FOR LEAD THERAPEUTIC COMPOUND VAL201 London, UK ., 08 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel techn...

ValiRx loan draw down

ValiRx has drawn down the second tranche of its convertible loan facility with YA Global Master SPV Ltd for the amoun...

Convertible Loan Facility

RNS Number: 8716Q ValiRx PLC 02 December 2016 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Convertible Loan Facility London, UK ., 02 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commerci...

Fundamental DataMore

EPS-6.66
Dividend yield0 %

Equity Research (VAL)

edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

  • Milestone

    Didn't we recently pass 10 billion shares (old money) in issue? I betcha we hit 20 billion in a year and a half @ as low as 2p. Then we can slide all the way down to 0.1p ...
    20-Jan-2017
    Geoffss
  • Deal day

    After the lack of price rise on what I thought was a very promising RNS...I realise that the SP will only take off when a partnership deal is announced. But the day that ...
    13-Jan-2017
    southernstar
  • Re: Dilution

    I think the issue is that a 30% dilution results in a 30%-50% drop in the share price, with no guarantee of any business growth. but hey if you're happy with that then fair ...
    12-Jan-2017
    fragma1

Users' HoldingsMore

Users who hold Valirx also hold..
SOUND ENERGY18%
ROCKHOPPER17%
RANGE RES.17%
SAREUM16%
LLOYDS GRP.16%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL